Sarozar tablet is indicated for the treatment of diabetic dyslipidemia and hypertriglyceridemia with Type 2 diabetes mellitus not controlled by statin therapy. In clinical studies, Sarozar tablet has demonstrated reduction of triglycerides (TG), Low Density Lipoprotein (LDL) cholesterol, Very Low Density Lipoprotein (VLDL) cholesterol, non-High Density Lipoprotein (non- HDL) cholesterol and an increase in HDL cholesterol. It has also shown favorable glycemic indices by reducing the fasting plasma glucose and glycosylated hemoglobin in diabetic patients.
